BR112015022292A2 - processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro - Google Patents
processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soroInfo
- Publication number
- BR112015022292A2 BR112015022292A2 BR112015022292A BR112015022292A BR112015022292A2 BR 112015022292 A2 BR112015022292 A2 BR 112015022292A2 BR 112015022292 A BR112015022292 A BR 112015022292A BR 112015022292 A BR112015022292 A BR 112015022292A BR 112015022292 A2 BR112015022292 A2 BR 112015022292A2
- Authority
- BR
- Brazil
- Prior art keywords
- manufacturing process
- cell culture
- culture system
- serum free
- lentiviral vectors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 238000004113 cell culture Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- 230000003466 anti-cipated effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Manufacturing & Machinery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787818P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030370 WO2014145578A1 (en) | 2013-03-15 | 2014-03-17 | Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015022292A2 true BR112015022292A2 (pt) | 2017-07-18 |
Family
ID=51538029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022292A BR112015022292A2 (pt) | 2013-03-15 | 2014-03-17 | processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20140323556A1 (enExample) |
| EP (1) | EP2970920B1 (enExample) |
| JP (1) | JP6480910B6 (enExample) |
| KR (1) | KR102200278B1 (enExample) |
| CN (2) | CN105378074A (enExample) |
| AU (1) | AU2014232879B2 (enExample) |
| BR (1) | BR112015022292A2 (enExample) |
| CA (1) | CA2904366C (enExample) |
| DK (1) | DK2970920T3 (enExample) |
| ES (1) | ES2681434T3 (enExample) |
| IL (1) | IL241058B (enExample) |
| MX (1) | MX364690B (enExample) |
| PT (1) | PT2970920T (enExample) |
| RU (1) | RU2709678C2 (enExample) |
| WO (1) | WO2014145578A1 (enExample) |
| ZA (1) | ZA201506478B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107530376A (zh) | 2015-02-18 | 2018-01-02 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| TWI547782B (zh) * | 2015-03-16 | 2016-09-01 | 智易科技股份有限公司 | 可擴充式製程系統與實現該系統的方法 |
| IL287500B2 (en) | 2015-04-21 | 2023-12-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| MX2018006682A (es) * | 2015-12-01 | 2018-09-26 | Spark Therapeutics Inc | Metodos escalables para producir vector viral adenoasociado (aav) recombinante en un sistema de cultivo celular en suspension libre de suero adecuado para su uso clinico. |
| CN107043784A (zh) * | 2016-02-05 | 2017-08-15 | 上海吉凯基因化学技术有限公司 | 一种慢病毒载体的制备方法 |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| CA3019126A1 (en) * | 2016-03-30 | 2017-10-05 | Spark Therapeutics, Inc. | Cell line for recombinant protein and/or viral vector production |
| AU2017249402A1 (en) | 2016-04-12 | 2018-10-04 | Artemis Biosystems, Inc. | Perfusion filtration systems |
| CN106497882A (zh) * | 2016-10-29 | 2017-03-15 | 复旦大学 | 同时过表达R‑spondin1和Noggin的细胞株及其构建方法和应用 |
| EP3420076B1 (en) | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| EP4382183A3 (en) | 2017-03-06 | 2024-08-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| CN109251939A (zh) * | 2017-07-14 | 2019-01-22 | 孙搏 | Il-17g-197a慢病毒表达载体、其构建方法及慢病毒的包装测定方法 |
| EP3754025A4 (en) * | 2018-01-24 | 2022-01-26 | Slbigen Inc. | Mesenchymal stem cells expressing brain-derived neurotrophic factor and use thereof |
| CN110317832B (zh) * | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN111763238B (zh) * | 2019-04-02 | 2022-07-29 | 普莱柯生物工程股份有限公司 | 一种蛋白抗原的纯化方法、制备的蛋白抗原及其应用 |
| US12565645B2 (en) * | 2019-04-11 | 2026-03-03 | Regenxbio Inc. | Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions |
| CN110054678B (zh) * | 2019-05-16 | 2023-04-18 | 中国医学科学院血液病医院（血液学研究所） | 一种膜结合型mFLT3LG蛋白及其应用 |
| US20220282281A1 (en) * | 2019-08-05 | 2022-09-08 | Polyplus Transfection | Compositions for transfecting a nucleic acid molecule into a cell comprising triazole compounds grafted to a cationic polymer, and their applications |
| KR20220047635A (ko) | 2019-08-23 | 2022-04-18 | 론자 워커스빌 아이엔씨. | 렌티바이러스 벡터의 생산을 위한 방법 및 작제물 |
| CN110894494B (zh) * | 2019-11-22 | 2022-09-27 | 广西梧州制药（集团）股份有限公司 | 一种大规模高密度悬浮培养293细胞高产腺病毒的方法 |
| CN110938654A (zh) * | 2019-12-11 | 2020-03-31 | 和元生物技术（上海）股份有限公司 | 一种细胞转染试剂及其应用 |
| CN113122501B (zh) * | 2019-12-30 | 2023-06-16 | 重庆精准生物技术有限公司 | 适合大规模临床级病毒载体制备的培养基及其应用 |
| JP2023528776A (ja) * | 2020-06-11 | 2023-07-06 | ２セブンティ バイオ インコーポレイテッド | ウイルスベクターの製造方法 |
| EP4196596A4 (en) * | 2020-08-13 | 2025-01-01 | Tmunity Therapeutics Inc. | METHOD FOR PRODUCING A CLINICAL QUALITY LENTIVIRAL VECTOR |
| CN112746076B (zh) * | 2020-12-28 | 2023-05-12 | 中吉智药(南京)生物技术有限公司 | 一种密码子优化的col7a1基因及慢病毒和应用 |
| JP2024504914A (ja) * | 2020-12-29 | 2024-02-02 | 江▲蘇▼金斯瑞蓬勃生物科技有限公司 | 高分散性ｈｅｋ２９３ｔ細胞株及びそのスクリーニング方法 |
| TW202309294A (zh) * | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
| EP4373951A1 (en) * | 2021-07-19 | 2024-05-29 | 2seventy bio, Inc. | Vector manufacturing processes |
| CN113980916B (zh) * | 2021-09-27 | 2024-11-05 | 湖南丰晖生物科技有限公司 | 一种慢病毒的纯化方法 |
| CN118660958A (zh) * | 2021-10-12 | 2024-09-17 | 江苏金斯瑞蓬勃生物科技有限公司 | 适应无血清悬浮培养的hek293细胞株及其应用 |
| CN114990077A (zh) * | 2022-08-01 | 2022-09-02 | 深圳市先康达生命科学有限公司 | 一种慢病毒包装与纯化方法 |
| CN116240241A (zh) * | 2022-12-30 | 2023-06-09 | 上海本导基因技术有限公司 | 重组慢病毒载体的纯化制备方法 |
| IN202321021121A (enExample) * | 2023-03-24 | 2024-04-19 | ||
| KR20250172638A (ko) * | 2023-04-12 | 2025-12-09 | 씨티바 바이오프로세스 알＆디 에이비 | 크로마토그래피 시스템, 그의 용도, 및 외피보유 또는 멤브레인성 생물학적 입자를 분리하는 방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
| US20030157070A1 (en) * | 1994-12-30 | 2003-08-21 | Jolly Douglas J. | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations |
| US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US7575924B2 (en) * | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
| JP2005523722A (ja) * | 2002-04-30 | 2005-08-11 | オンコリティクス バイオテック， インコーポレイティッド | 改善されたウイルス精製方法 |
| WO2005035743A1 (en) * | 2003-10-15 | 2005-04-21 | Vector Gene Technology Company Ltd. | Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors |
| ES2608638T3 (es) * | 2005-07-06 | 2017-04-12 | Ge Healthcare Bioprocess R&D Ab | Método para preparar una matriz de separación |
| WO2008148304A1 (en) * | 2007-05-31 | 2008-12-11 | Xiamen University | Rna interference target for treating aids |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| WO2009153563A1 (en) * | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| KR20110074564A (ko) * | 2008-09-24 | 2011-06-30 | 메디뮨 엘엘씨 | 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법 |
| KR101812813B1 (ko) * | 2009-06-16 | 2017-12-27 | 젠자임 코포레이션 | 재조합 ａａｖ 벡터에 대한 개선된 정제 방법 |
| SG182490A1 (en) | 2010-01-12 | 2012-08-30 | Vascular Biogenics Ltd | Methods of producing adenovirus vectors and viral preparations generated thereby |
| WO2011097447A2 (en) * | 2010-02-04 | 2011-08-11 | Neurologix, Inc. | Production of recombinant virus |
-
2014
- 2014-03-17 MX MX2015012450A patent/MX364690B/es active IP Right Grant
- 2014-03-17 CA CA2904366A patent/CA2904366C/en active Active
- 2014-03-17 EP EP14762249.2A patent/EP2970920B1/en active Active
- 2014-03-17 JP JP2016503383A patent/JP6480910B6/ja active Active
- 2014-03-17 DK DK14762249.2T patent/DK2970920T3/en active
- 2014-03-17 BR BR112015022292A patent/BR112015022292A2/pt not_active Application Discontinuation
- 2014-03-17 RU RU2015144057A patent/RU2709678C2/ru active
- 2014-03-17 WO PCT/US2014/030370 patent/WO2014145578A1/en not_active Ceased
- 2014-03-17 KR KR1020157029322A patent/KR102200278B1/ko active Active
- 2014-03-17 AU AU2014232879A patent/AU2014232879B2/en active Active
- 2014-03-17 CN CN201480016236.2A patent/CN105378074A/zh active Pending
- 2014-03-17 CN CN202410062902.1A patent/CN118256453A/zh active Pending
- 2014-03-17 ES ES14762249.2T patent/ES2681434T3/es active Active
- 2014-03-17 US US14/216,778 patent/US20140323556A1/en not_active Abandoned
- 2014-03-17 PT PT147622492T patent/PT2970920T/pt unknown
-
2015
- 2015-09-02 IL IL241058A patent/IL241058B/en active IP Right Grant
- 2015-09-03 ZA ZA2015/06478A patent/ZA201506478B/en unknown
-
2017
- 2017-09-08 US US15/699,613 patent/US10994028B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512700A (ja) | 2016-05-09 |
| MX364690B (es) | 2019-05-06 |
| IL241058B (en) | 2020-05-31 |
| CA2904366A1 (en) | 2014-09-18 |
| MX2015012450A (es) | 2016-04-25 |
| JP6480910B6 (ja) | 2019-04-03 |
| RU2015144057A (ru) | 2017-04-27 |
| DK2970920T3 (en) | 2018-08-06 |
| PT2970920T (pt) | 2018-07-30 |
| AU2014232879A1 (en) | 2015-09-24 |
| IL241058A0 (en) | 2015-11-30 |
| JP6480910B2 (ja) | 2019-03-13 |
| US20170368201A1 (en) | 2017-12-28 |
| US20140323556A1 (en) | 2014-10-30 |
| KR102200278B1 (ko) | 2021-01-07 |
| RU2709678C2 (ru) | 2019-12-19 |
| ES2681434T3 (es) | 2018-09-13 |
| HK1219978A1 (en) | 2017-04-21 |
| AU2014232879B2 (en) | 2020-03-05 |
| CA2904366C (en) | 2023-07-04 |
| ZA201506478B (en) | 2021-09-29 |
| KR20160024841A (ko) | 2016-03-07 |
| CN118256453A (zh) | 2024-06-28 |
| EP2970920A4 (en) | 2016-09-14 |
| US10994028B2 (en) | 2021-05-04 |
| CN105378074A (zh) | 2016-03-02 |
| EP2970920B1 (en) | 2018-04-25 |
| EP2970920A1 (en) | 2016-01-20 |
| WO2014145578A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX364690B (es) | Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero. | |
| IL259595B1 (en) | Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use | |
| BR112014019901A8 (pt) | Proteínas de fator viii recombinante | |
| DOP2014000294A (es) | Purificación de iduronato 2 sulfatasa | |
| PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
| BR112014032560A2 (pt) | células para produzir iduronato-2-sulfatase recombinante | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| WO2012031263A3 (en) | Cell culture system for bioreactor scale-up of cells | |
| MY166059A (en) | Fusion Proteins for Treating Metabolic Disorders | |
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| BR112012011740A2 (pt) | polipeptídeo, composição compreendendo o referido polipeptídeo, complexo de proteína, seqüência de nucleotídeo, vetor de expressão célula, e métodos para a preparação do complexo de proteína, para a preparação de um fviii, e para intensificar uma propriedade farmacocinética no plasma de um fviii | |
| AR088252A1 (es) | Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris | |
| WO2012068317A3 (en) | Methods for producing recombinant proteins | |
| BR112016006606A2 (pt) | Molécula de ácido nucléico recombinante, molécula de aminoácido recombinante, construção de expressão recombinante, vetor recombinante, micro-organismo recombinante, composição, método de produção de aminoácidos, uso de uma molécula de ácido nucléico e processo de produção fermentativa | |
| BR112015021189A2 (pt) | métodos de banco de células de alta densidade | |
| BR112015022529A2 (pt) | meios de cultura de células e processos de produção de anticorpo | |
| BR112014015357A2 (pt) | método para a preparação de partículas de proteína precipitada amorfa | |
| BR112015021586A2 (pt) | formulações de morfina | |
| CR20140587A (es) | Metodo para producir iduronato-2-sulfatasa recombinante | |
| IN2015DN03206A (enExample) | ||
| BR112014002173A2 (pt) | proteínas purificadas | |
| BR112017013576A2 (pt) | produção melhorada de lipídios de núcleo em leveduras oleaginosas | |
| IN2014CN03414A (enExample) | ||
| AU2011311637A8 (en) | Methods for semi-synthetically producing highly pure minicircle DNA vectors from plasmids | |
| BR112014008225A2 (pt) | sistemas de purificação de vetores virais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |